Global Non-Invasive Prenatal Testing Market Report by Component (Instruments, Kits and Reagents, Services) Application (Down Syndrome (trisomy 21), Edwards Syndrome (trisomy 18), Patau Syndrome (trisomy 13), Turner Syndrome, Other Applications) End User (Hospitals, Diagnostic Labs) Countries and Company Analysis, 2024-2032

Driving forces for Non-Invasive Prenatal Testing Market

Growing Chromosomal Abnormality Prevalence Will Raise Need for These Tests - The age at which mothers become childbearing has changed recently as a result of several social and economic variables. As to a recent NBC News article, the average age of American women giving birth has risen from 27 to 30 years old. The CDC states that women who are 35 years of age or older have a higher risk of having a baby affected by Down syndrome compared to those who become pregnant earlier in life. The aforementioned factors are connected and have resulted in a higher incidence of Down syndrome and other genetic problems in neonates.

Furthermore, the WHO factsheet from February 2023 states that every year, roughly 170,000 children between the ages of one month and five years old and 240,000 infants perish within 28 days. This has led to the early use of prenatal testing, including non-invasive ones, for the screening of expectant mothers.

Additionally, encouraging reimbursement practices and increasing public knowledge of the benefits of non-invasive prenatal testing versus invasive procedures are anticipated to boost their use over the projection period.

Continuous Product Innovations to Support Market Expansion - Many businesses are continuously concentrating on creating extremely sophisticated screening technologies that are highly precise and sensitive in identifying genetic diseases in infants at an early age. To improve their market positions, manufacturers are putting more emphasis on the creation of cutting-edge non-invasive prenatal testing and forming strategic alliances and partnerships. Significant progress has been made in identifying aneuploidies in the newborn population thanks to human genome sequencing. For example, the United States-based molecular diagnostic business BillionToOne Inc. announced in September 2022 the introduction of the UNITY fetal antigen single-gene non-invasive prenatal test (sgNIPT). The test is available at 10+ weeks gestation and detects the genetic variations that code for the associated fetal antigens.

Furthermore, a lot of nations are implementing screening laws that involve non-invasive prenatal testing for chromosomal abnormalities

For example, a December 2022 article in the European Journal of Human Genetics reports that some European nations are incorporating non-invasive prenatal testing into their publicly funded healthcare systems in order to screen for chromosomal aneuploidies. Additionally, these examinations started to be covered by the German government in 2022.

North America Non-Invasive Prenatal Testing Market

Over the course of the forecast period, North America is anticipated to maintain its dominant position in the non-invasive prenatal testing (NIPT) market. In this area, the prevalence of chromosomal abnormalities, high rates of preterm births, and high rates of maternal death will probably lead to a rise in the use and demand for testing. Numerous studies shed light on the efficacy of raising awareness of prenatal care. For example, a research paper released in August 2022 by the National Library of Medicine said that improvements in prenatal care have raised awareness of fetal deformities, and that malpresentation is anticipated to enhance readiness for a high-risk delivery. Therefore, for best results, pregnant women should follow prenatal care guidelines.

Because of the increased awareness of chromosomal disorders in fetuses, North America is predicted to lead the non-invasive prenatal testing (NIPT) market over the forecast period.

Additionally, the development of new, technologically improved tests, increased adoption and awareness among the populace, and high diagnostic rates are all fueling the market's expansion in North America.

For example, in May 2021, Yourgene introduced IONA Care, a non-invasive prenatal test (NIPT) service that measures the likelihood that a pregnant woman is carrying a fetus with autosomal aneuploidies (AA) and sex chromosome aneuploidies (SCA), in addition to the existing IONA test, which provides fetal sex determination and screening for trisomies 21, 18, and 13. Over the course of the projection year, it is anticipated that these product introductions would boost market growth.

Non-Invasive Prenatal Testing Company Overview

The leading market players in the Non-Invasive Prenatal Testing market are Eurofins Scientific, F. Hoffmann-La Roche Ltd, Invitae Corporation, Illumina Inc., Natera Inc., Centogene NV, Qiagen.

Non-Invasive Prenatal Testing Company News

• In September 2023, The Yourgene MagBench Automated DNA Extraction Instrument and Kit was introduced by Yourgene Health plc. The MagBench solution, designed specifically for Yourgene's Sage 32 NIPT Workflow, provides a fast, easy-to-use, and reasonably priced bench-top robotic workstation for cell-free DNA extraction. It is available to Sage clients in Asia-Pacific and the Middle East. This all-inclusive system ensured efficiency from sample to report and enabled clinical laboratories to provide accurate and competitive non-invasive prenatal testing (NIPT) services.

• In August 2022, as part of the Q-Sub process, Natera Inc. submitted a pre-submission for its panoramic non-invasive prenatal test (NIPT) to the Food and Drug Administration (FDA). In June 2022, the business submitted their pre-submission for 22q11.2 deletion syndrome and fetal chromosomal aneuploidies.

FAQS

Question:    How big is the Non-Invasive Prenatal Testing market?

Answer:     The global Non-Invasive Prenatal Testing market size was estimated to reach USD 9.98 billion in 2032 while it was estimated to reach US$ 3.19 billion by 2023.

Question:    What is the Non-Invasive Prenatal Testing market growth rate?

Answer:     The global Non-Invasive Prenatal Testing market is expected to grow at a compound annual growth rate of 13.51% from 2024 to 2032.

Question:    Who are the key players in Non-Invasive Prenatal Testing market?

Answer:     Some key players operating in the Non-Invasive Prenatal Testing market includes Eurofins Scientific, F. Hoffmann-La Roche Ltd, Invitae Corporation, Illumina Inc., etc.

Question:    What are the factors driving the Non-Invasive Prenatal Testing market?

Answer:     Key factors that are driving the Non-Invasive Prenatal Testing includes Growing Chromosomal Abnormality Prevalence Will Raise Need for These Tests, Continuous Product Innovations to Support Market Expansion etc.

Question:    Which Region held the largest market share in the Non-Invasive Prenatal Testing market?

Answer:     “North America” had the largest share in the Non-Invasive Prenatal Testing Market.

Component – Market in 3 Viewpoints:

1. Instruments
2. Kits and Reagents
3. Services

Application – Market in 5 Viewpoints:

1. Down Syndrome (trisomy 21)
2. Edwards Syndrome (trisomy 18)
3. Patau Syndrome (trisomy 13)
4. Turner Syndrome
5. Other Applications

End User – Market in 2 Viewpoints –

1. Hospitals
2. Diagnostic Labs

Geography – Global Non-Invasive Prenatal Testing Market

North America

1. United States
2. Canada

Europe

1. France
2. Germany
3. Italy
4. Spain
5. United Kingdom
6. Belgium
7. Netherlands
8. Turkey

Asia Pacific

1. China
2. Japan
3. India
4. Australia
5. South Korea
6. Thailand
7. Malaysia
8. Indonesia
9. New Zealand

Latin America

1. Brazil
2. Mexico
3. Argentina

Middle East & Africa

1. South Africa
2. Saudi Arabia
3. United Arab Emirates

Company Insights:

• Overviews
• Recent Developments & Strategies
• Revenue

Company Analysis:

1. Eurofins Scientific
2. Hoffmann-La Roche Ltd
3. Invitae Corporation
4. Illumina Inc.
5. Natera Inc.
6. Centogene NV
7. Qiagen

Report Details: